Orphazyme A/S
CSE:ORPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tay Two Co Ltd
TSE:7610
|
JP |
|
L
|
L'Oreal SA
XETRA:LOR
|
FR |
|
Fino Payments Bank Ltd
NSE:FINOPB
|
IN |
|
Sonam Ltd
NSE:SONAMLTD
|
IN |
|
Disc Medicine Inc
NASDAQ:IRON
|
US |
|
H
|
Hanall Biopharma Co Ltd
KRX:009420
|
KR |
|
Goldman Sachs BDC Inc
NYSE:GSBD
|
US |
|
C
|
Century Ginwa Retail Holdings Ltd
HKEX:162
|
HK |
|
A
|
American Salars Lithium Inc
OTC:ASALF
|
CA |
|
Nova Cannabis Inc
TSX:NOVC
|
CA |
|
Geox SpA
MIL:GEO
|
IT |
|
F
|
Fuji Seal International Inc
TSE:7864
|
JP |
Orphazyme A/S
EPS (Diluted)
Orphazyme A/S
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orphazyme A/S
CSE:ORPHA
|
EPS (Diluted)
-kr737
|
CAGR 3-Years
-221%
|
CAGR 5-Years
-130%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
EPS (Diluted)
kr15
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
EPS (Diluted)
kr91
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Galecto Inc
NASDAQ:GLTO
|
EPS (Diluted)
-$18
|
CAGR 3-Years
-108%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
EPS (Diluted)
-€3
|
CAGR 3-Years
29%
|
CAGR 5-Years
15%
|
CAGR 10-Years
-10%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
EPS (Diluted)
kr17
|
CAGR 3-Years
N/A
|
CAGR 5-Years
28%
|
CAGR 10-Years
27%
|
|
Orphazyme A/S
Glance View
Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The firm collaborates with academic institutions in Europe and the United States.
See Also
What is Orphazyme A/S's EPS (Diluted)?
EPS (Diluted)
-737.7
DKK
Based on the financial report for Dec 31, 2023, Orphazyme A/S's EPS (Diluted) amounts to -737.7 DKK.
What is Orphazyme A/S's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-130%
The average annual EPS (Diluted) growth rates for Orphazyme A/S have been -221% over the past three years , -130% over the past five years .
